logo

PRLD

Prelude·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

PRLD fundamentals

Prelude (PRLD) released its earnings on Nov 12, 2025: revenue was 6.50M (YoY +116.67%), beat estimates; EPS was -0.26 (YoY +39.53%), beat estimates.
Revenue / YoY
6.50M
+116.67%
EPS / YoY
-0.26
+39.53%
Report date
Nov 12, 2025
PRLD Earnings Call Summary for Q3,2025
  • Two Lead Programs in 2026: JAK2V617F inhibitor for MPN and KAT6A degrader for ER+ breast cancer.
  • Incyte Deal: $60M upfront, up to $910M total, leveraging Incyte's MPN expertise.
  • Selective Degradation: KAT6A degrader avoids dual inhibition toxicity, showing preclinical efficacy.
  • Clinical Timelines: JAK2 Phase I H1 2026, KAT6A Phase I H2 2026.
EPS
Revenue

Revenue & Expenses

PRLD has released its 2025 Q3 earnings report, with revenue of 6.50M, reflecting a YoY change of 116.67%, and net profit of -19.73M, showing a YoY change of 38.88%. The Sankey diagram below clearly presents PRLD's revenue sources and cost distribution.

Key Indicators

Prelude (PRLD) key financial stats and ratios, covering profitability, financial health, and leverage.
Prelude (PRLD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Prelude (PRLD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Prelude (PRLD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Prelude (PRLD) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Prelude (PRLD) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield